Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel like decoding a laboratory notebook. Alnylam Pharmaceuticals’ RNAi pipeline spans rare-disease trials, partnership milestones, and intricate cash-flow disclosures—details scattered across hundreds of pages. If you’ve searched for “Alnylam SEC filings explained simply” or wondered how to spot pivotal RNAi data buried in its 10-K, you’re not alone.
Stock Titan solves that problem in minutes. Our AI parses every Alnylam quarterly earnings report 10-Q filing, tags key metrics like cash runway, and delivers real-time alerts on Alnylam Form 4 insider transactions—so you never miss a chief scientist’s stock move. Need the Alnylam annual report 10-K simplified? We highlight pipeline progress, collaboration revenue, and patent cliffs. Curious about “Alnylam 8-K material events explained”? We translate FDA designations, partnership amendments, and trial readouts into plain English. From Alnylam executive stock transactions Form 4 to the proxy statement executive compensation tables, all documents stream directly from EDGAR with instant AI summaries.
Use cases investors rely on:
- Monitor Alnylam insider trading Form 4 transactions before material announcements
- Compare RNAi program spending across each Alnylam earnings report filing analysis
- Review Alnylam proxy statement executive compensation to gauge R&D incentives
- Track Alnylam quarterly earnings report 10-Q filing for clinical-trial cash needs
- Receive Alnylam Form 4 insider transactions real-time for sentiment signals
Understanding Alnylam SEC documents with AI means faster decisions based on the disclosures that actually move a biotech stock.
Alnylam Pharmaceuticals announced significant organizational changes with the combination of its Research and Early Development function and Development function into a single R&D organization. Key leadership appointments include:
- Dr. Pushkal Garg promoted to Executive VP, Chief Research and Development Officer with new compensation package: - Base salary: $825,000 - Annual incentive target: 65% of base salary - Long-term equity incentives to be determined
- Dr. Kevin Fitzgerald (Executive VP, Chief Scientific Officer) receives expanded responsibilities for external innovation with: - Increased annual incentive target to 60% of base salary - One-time restricted stock unit grant valued at $2.5M, vesting over 3 years
This strategic reorganization aims to streamline R&D operations and strengthen the company's innovation capabilities. The changes were approved by the People, Culture and Compensation Committee on June 12, 2025, with formal announcement made on June 18, 2025.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
What is Alnylam Pharmaceuticals known for?
How does RNAi technology work in Alnylam's treatments?
Which therapeutic areas does Alnylam focus on?
What role do strategic partnerships play in Alnylam's business model?
How does Alnylam differentiate itself in the competitive biopharmaceutical market?
What are some common industry terms associated with Alnylam Pharmaceuticals?
